Last updated on September 2018

Study of REGN2810 and REGN1979 in Patients With Lymphoma


Brief description of study

This is an open-label, multicenter, dose escalation study of REGN2810 and REGN1979 in patients with lymphoma. The study treatment period will be from 6 to 12 months, depending on how an individual patient responds to treatment. The follow-up period will be 6 months for all patients.

Clinical Study Identifier: NCT02651662

Find a site near you

Start Over